½ÃÀ庸°í¼­
»óǰÄÚµå
1577050

½ÅÀå °á¼® °ü¸® ½ÃÀå, ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®°ú ¿¹Ãø(2024-2032³â)

Kidney Stone Management Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 263 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ½ÅÀå °á¼® °ü¸® ½ÃÀåÀº 2023³â¿¡´Â ¾à 26¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, 2032³â¿¡´Â CAGR 5.1%·Î ¾à 41¾ï ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÅÀå °á¼®ÀÇ À¯º´·ü Áõ°¡, ³ôÀº Àç¹ß·ü, Ä¡·á¸¦ À§ÇÑ Ã·´Ü ±â¼ú ¼Ö·ç¼ÇÀÇ °³¹ßÀÌ ÀÌ·¯ÇÑ ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ½ÅÀå °á¼®Àº ¿ä·Î À̵¿½Ã Å« ÅëÁõÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¸ç, Àα¸ °í·ÉÈ­¿Í ¼Ò±Ý, ´Ü¹éÁú, ¿Á»ì»ê ¿°ÀÌ ¸¹Àº ½Ä´Ü°ú °°Àº »ýȰ½À°ü ¿äÀÎÀ¸·Î ÀÎÇØ Á¡Á¡ ´õ ÈçÇØÁö°í ÀÖ½À´Ï´Ù.

½ÅÀå °á¼® °ü¸®¿¡´Â °á¼® Çü¼ºÀ» ÁÙÀ̱â À§ÇÑ ´Ù¾çÇÑ Ä¡·á, Áø´Ü Åø ¹× ¿¹¹æ Àü·«ÀÌ Æ÷ÇԵ˴ϴÙ. ½ÃÀåÀº °á¼® À¯Çü¿¡ µû¶ó ºÐ·ùµÇ¸ç, ¿Á»ì»êÄ®½· °á¼®ÀÌ °¡Àå ¸¹À¸¸ç 75-80%¸¦ Â÷ÁöÇϸç, 2023³â ¿Á»ì»êÄ®½· ºÎ¹® ¸ÅÃâÀº 19¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ °á¼®ÀÇ À§Çè ¿äÀο¡´Â Ä®½·ÀÇ °ú´Ù ¼·Ãë¿Í ÇÔ²² ½Ã±ÝÄ¡, °ß°ú·ù µî ¿Á»ì»ê ¿°ÀÌ ¸¹ÀÌ ÇÔÀ¯µÈ ½Ä´ÜÀÌ Æ÷ÇԵ˴ϴÙ.

ÀÌ ½ÃÀåÀÇ Áø´Ü¿¡´Â º¹ºÎ ¿¢½º·¹ÀÌ, CT ½ºÄµ, ÃÊÀ½ÆÄ, MRI, Á¤¸Æ³» ½Å¿ì½Å Á¶¿µ¼ú µîÀÌ Æ÷ÇԵǸç, CT ½ºÄµÀº 2023³â ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2032³â ½ÃÀå ±Ô¸ð´Â 13¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.ÀÇ ¸Å·ÂÀº ½Å¼ÓÇÏ°í ºñħ½ÀÀûÀΠƯ¼ºÀ¸·Î, ƯÈ÷ ÀÀ±Þ»óȲ¿¡¼­ À¯¿ëÇÕ´Ï´Ù.

½ÅÀå °á¼® Ä¡·á¹ý¿¡´Â ü¿ÜÃæ°ÝÆÄ¼â¼®¼ú(ESWL), ¿ä°ü°æ °Ë»ç, °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú(PCNL) µîÀÌ ÀÖÀ¸¸ç, ESWLÀº 2023³â ½ÃÀå Á¡À¯À² 58.2%¸¦ Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ÀÌ ºñħ½ÀÀû ½Ã¼úÀº Ãæ°ÝÆÄ¸¦ »ç¿ëÇÏ¿© °á¼®À» ºÐÇØÇϰí Åë°ú¸¦ ¿ëÀÌÇÏ°Ô ÇÏ´Â ºñħ½ÀÀû ½Ã¼ú·Î, Ä®½· ¿Á»ì»êÀ̳ª ¿ä»ê°ú °°Àº °á¼®¿¡ ƯÈ÷ È¿°úÀûÀÔ´Ï´Ù.

º´¿øÀº ½ÅÀå °á¼® °ü¸® ½ÃÀå¿¡¼­ °¡Àå Å« ÃÖÁ¾ »ç¿ëó·Î 2023³â 13¾ï ´Þ·¯ ±Ô¸ð ½ÃÀåÀ» âÃâÇß½À´Ï´Ù. º´¿øÀº ±Þ¼º ½ÅÀå »êÅë°ú °°Àº ÀÀ±Þ »óȲ¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â ½Ã¼³À» °®Ãß°í ÀÖÀ¸¸ç, ·¹ÀÌÀú °á¼® ºÐ¼â±â, ¼ö¼ú ·Îº¿ µî ÷´Ü ±â¼úÀ» Á¦°øÇÕ´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 11¾ï ´Þ·¯·Î 2023³â ½ÃÀåÀ» ¼±µµÇß½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ³ôÀº ½ÅÀå °á¼® À¯º´·üÀº ½Ä½À°ü ¹× »ýȰ½À°ü ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ ÀÌ Áö¿ªÀÇ Ã·´ÜÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó´Â Á¾ÇÕÀûÀÎ ½ÅÀå °á¼® °ü¸®¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • ¼¼°è¿¡¼­ ½ÅÀå °á¼®ÀÇ À¯º´·ü°ú Àç¹ß·üÀÇ Áõ°¡
      • ¿ä°ü°æ ±â¼úÀÇ Áøº¸
      • °á¼®ÆÄ¼â ½Ã¼ú¿¡ ´ëÇÑ À¯¸®ÇÑ »óȯ Á¦µµ
      • Àúħ½À¼ö¼ú¿¡ ´ëÇÑ ÁöÇâ
      • ½ÅÀå °Ç°­ Àü¹Ý¿¡ °üÇÑ ÀǽÄÀÇ Çâ»ó
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • ƯÁ¤ ±¹°¡¿¡¼­ Ä¡·á ÀǽÄÀÇ °á¿©
      • °á¼®ÆÄ¼â¼úÀÇ Àå±âÀû ºÎÀÛ¿ë °¡´É¼º
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±â¼ú Àü¸Á
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • ±ÔÁ¦ »óȲ
  • »óȯ ½Ã³ª¸®¿À
  • °¸ ºÐ¼®
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : À¯Çüº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ¿Á»ì»êÄ®½·
  • ÀλêÄ®½·
  • ¿ä»ê
  • ½ºÆ®·ç¹ÙÀÌÆ®
  • ½Ã½ºÅ×ÀÎ

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áø´Üº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º¹ºÎ X¼±
  • ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ
  • ÃÊÀ½ÆÄ
  • º¹ºÎ MRI
  • Á¤¸Æ³» ½Å¿ìÁ¶¿µ
  • ±âŸ Áø´Ü

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Ä¡·áº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º¹ºÎ X¼±
  • ü¿Ü Ãæ°ÝÆÄ °á¼®ÆÄ¼â¼ú(ESWL)
  • ¿ä°ü°æ °Ë»ç
  • °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú(PCNL)
  • ±âŸ Ä¡·á

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • Àü¹® Ŭ¸®´Ð
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦9Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ±â¾÷ °³¿ä

  • Allengers Medical Systems Ltd
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Coloplast A/S
  • Cook Medical LLC
  • DirexGroup
  • Dornier MedTech
  • EDAP TMS S.A
  • Elmed Medical Systems
  • Karl Storz GmbH
  • Medispec Ltd
  • Olympus Corporation
  • Richard Wolf GmbH
  • Siemens Healthineers
KSA 24.11.06

The Global Kidney Stone Management Market was valued at approximately USD 2.6 billion in 2023 and is projected to grow to around USD 4.1 billion by 2032, with a CAGR of 5.1%. This growth is largely driven by the increasing prevalence of kidney stones, their high recurrence rates, and the ongoing development of advanced technological solutions for treatment. Kidney stones, which can cause significant pain as they move through the urinary tract, are becoming more common due to aging populations and lifestyle factors, such as diets high in salt, protein, and oxalates.

Kidney stone management involves a range of medical treatments, diagnostic tools, and preventative strategies aimed at reducing stone formation. The market is segmented by stone type, with calcium oxalate stones being the most prevalent, representing 75-80% of cases. In 2023, the calcium oxalate segment generated USD 1.9 billion in revenue. Risk factors for these stones include diets rich in oxalates, such as spinach and nuts, along with high calcium intake.

Diagnostics in this market include abdominal x-rays, CT scans, ultrasounds, MRIs, and intravenous pyelography. CT scans led the market in 2023, and their popularity is expected to continue growing, with a projected market value of USD 1.3 billion by 2032. The appeal of CT scans lies in their rapid, non-invasive nature, making them particularly useful in emergency settings.

Treatment methods for kidney stones include extracorporeal shock wave lithotripsy (ESWL), ureteroscopy, and percutaneous nephrolithotomy (PCNL). ESWL dominated the market in 2023, accounting for 58.2% of the market share. This non-invasive technique uses shock waves to break down stones for easier passage and is especially effective for stones like calcium oxalate and uric acid.

Hospitals were the largest end use rs in the kidney stone management market, generating USD 1.3 billion in 2023. Hospitals are equipped to handle emergencies such as acute renal colic and offer advanced technologies, such as laser lithotripters and surgical robots, which are key drivers for this segment.

Regionally, North America led the market in 2023 with a value of USD 1.1 billion. The region's high prevalence of kidney stones is attributed to dietary and lifestyle factors. Additionally, the region's advanced healthcare infrastructure supports comprehensive kidney stone management.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence and recurrence rate of kidney stones globally
      • 3.2.1.2 Advancements in ureteroscopy technique
      • 3.2.1.3 Favourable reimbursement for lithotripsy procedures
      • 3.2.1.4 Inclination towards undergoing minimally invasive surgeries
      • 3.2.1.5 Rising awareness regarding overall kidney health
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Lack of treatment awareness in certain countries
      • 3.2.2.2 Potential long-term adverse effects of lithotripsy
  • 3.3 Growth potential analysis
  • 3.4 Technology landscape
  • 3.5 Future market trends
  • 3.6 Regulatory landscape
  • 3.7 Reimbursement scenario
  • 3.8 Gap analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Calcium oxalate
  • 5.3 Calcium phosphate
  • 5.4 Uric acid
  • 5.5 Struvite
  • 5.6 Cysteine

Chapter 6 Market Estimates and Forecast, By Diagnostics, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Abdominal x-ray
  • 6.3 Computed tomography
  • 6.4 Ultrasound
  • 6.5 Abdominal MRI
  • 6.6 Intravenous pyelography
  • 6.7 Other diagnostics

Chapter 7 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Abdominal x-ray
  • 7.3 Extracorporeal shock wave lithotripsy (ESWL)
  • 7.4 Ureteroscopy
  • 7.5 Percutaneous nephrolithotomy (PCNL)
  • 7.6 Other treatments

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Specialty clinics
  • 8.4 Ambulatory surgical centers
  • 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Allengers Medical Systems Ltd
  • 10.2 Becton, Dickinson and Company
  • 10.3 Boston Scientific Corporation
  • 10.4 Coloplast A/S
  • 10.5 Cook Medical LLC
  • 10.6 DirexGroup
  • 10.7 Dornier MedTech
  • 10.8 EDAP TMS S.A
  • 10.9 Elmed Medical Systems
  • 10.10 Karl Storz GmbH
  • 10.11 Medispec Ltd
  • 10.12 Olympus Corporation
  • 10.13 Richard Wolf GmbH
  • 10.14 Siemens Healthineers
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦